Anthony J. Bench

TL;DR: A single acquired mutation of JAK2 was noted in more than half of patients with a myeloproliferative disorder and its presence in all erythropoietin-independent erythroid colonies demonstrates a link with growth factor hypersensitivity, a key biological feature of these disorders.

TL;DR: The results suggest that JAK2 V617F-positive essential thrombocythaemia and polycythaemia vera form a biological continuum, with the degree of erythrocytosis determined by physiological or genetic modifiers.

TL;DR: It is demonstrated that MPL mutations outside exon 10 are uncommon in platelet cDNA and 4 different exon10 mutations in granulocyte DNA from a retrospective cohort of 200 patients with ET or IMF are identified.

TL;DR: It is demonstrated that patients with V617F(-) essential thrombocythemia do not commonly progress to become V617f(+), and inherent XCIP variability between granulocytes and T cells produces a systematically biased pattern of results that may be misinterpreted as evidence for an excess of clonally derived granulocyte-T cells, an observation that limits the utility ofXCIP analysis.

TL;DR: The results indicate that deletions occur at the time of the Philadelphia (Ph) translocation and may result in considerable genetic heterogeneity ab initio, a concept that is likely to apply to other malignancies associated with translocations.